FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed is a binding domain against EGFRvIII, comprising a chimeric antigenic receptor encoding nucleic acids, a vector, a cell, as well as use of said inventions in the manufacture of a medicament, methods of producing a cell and obtaining a population of cells, a method for providing immunity, a method of treating.
EFFECT: present invention can find further application in therapy using adaptive cell transfer.
103 cl, 18 dwg, 9 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC ANTIGEN RECEPTORS AND THEIR PRODUCTION METHODS | 2015 |
|
RU2753965C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
Authors
Dates
2019-12-03—Published
2014-02-20—Filed